Main navigation

Products we regulate
Product safety
How we regulate
Guidance and resources

Boehringer Ingelheim Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

ARTG (87)
Cancellation by sponsor (44)
Prescription medicine registration (10)
Australian Public Assessment Report (AusPAR) (7)
Designation or determination (2)
Prescription medicine decision summary (1)
Prescription medicine evaluation (1)

Date

2024 (6)
2023 (9)
2022 (3)
2021 (6)
2020 (14)
2019 (2)
2018 (15)
2017 (4)
2016 (16)
2015 (13)
2014 (4)
2013 (14)
2012 (3)
2011 (8)
2010 (5)
2008 (4)
2007 (2)
2003 (1)
2002 (3)
2001 (4)
2000 (3)
1999 (7)
1998 (1)
1996 (1)
1993 (1)
1992 (1)
1991 (2)

Results for "[search-keyword]"

Search

Sponsor content

152 result(s) found, displaying 11 to 20

ESOVYND RESPIMAT tiotropium 2.5 micrograms/actuation solution for inhalation cartridge Cancelled under Section 30(1)(c) of the Act

8 May 2023

Cancellation by sponsor

Requested by Boehringer Ingelheim Pty Ltd
YANIMO RESPIMAT 2.5 micrograms/2.5 micrograms tiotropium (as bromide monohydrate)/olodaterol (as hydrochloride) solution for inhalation cartridge Cancelled under Section 30(1)(c) of the Act

8 May 2023

Cancellation by sponsor

Requested by Boehringer Ingelheim Pty Ltd
SPIOLTO RESPIMAT 2.5 micrograms/2.5 micrograms tiotropium (as bromide monohydrate)/olodaterol (as hydrochloride) solution for inhalation cartridge Cancelled under Section 30(1)(c) of the Act

8 May 2023

Cancellation by sponsor

Requested by Boehringer Ingelheim Pty Ltd
STRIVERDI RESPIMAT olodaterol (as hydrochloride) 2.5 microgram/actuation solution for inhalation cartridge Cancelled under Section 30(1)(c) of the Act

8 May 2023

Cancellation by sponsor

Requested by Boehringer Ingelheim Pty Ltd
SPIRIVA RESPIMAT tiotropium 2.5 micrograms/actuation solution for inhalation cartridge Cancelled under Section 30(1)(c) of the Act

8 May 2023

Cancellation by sponsor

Requested by Boehringer Ingelheim Pty Ltd
JARDIANCE (Boehringer Ingelheim Pty Ltd)

12 December 2022

Prescription medicine registration

Active ingredients: empagliflozin.
APTIVUS tipranavir 250 mg soft capsule bottle Cancelled under Section 30(1)(c) of the Act

4 April 2022

Cancellation by sponsor

Requested by Boehringer Ingelheim Pty Ltd
Notice for spesolimab (Boehringer Ingelheim Pty Ltd)

14 January 2022

Designation or determination

Orphan drug
JARDIANCE (Boehringer Ingelheim Pty Ltd)

21 December 2021

Prescription medicine registration

Active ingredients: empagliflozin.
STRIVERDI RESPIMAT olodaterol (as hydrochloride) 2.5 microgram/actuation solution for inhalation cartridge (with dose indicator) (326012)

17 April 2020

ARTG

Australian Register of Therapeutic Goods (ARTG) information for STRIVERDI RESPIMAT olodaterol (as hydrochloride) 2.5 microgram/actuation solution for inhalation cartridge (with dose indicator).

Pages

First page
Previous page
Page 1
Current page 2
Page 3
Page 4
Page 5
Page 6
Page 7
Page 8
Page 9
…
Next page
Last page

Is there anything wrong with this page?

Help us improve the Therapeutic Goods Administration site

What were you doing? (mandatory)

What went wrong? (mandatory)

Leave this field blank

Using our website

Accessibility
Privacy
Disclaimer
Copyright
Freedom of information

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Subscribe to updates
Contact us
Facebook
(Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health and Aged Care acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.